Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 201,048 shares, a growth of 2,279.8% from the July 30th total of 8,448 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average daily volume of 399,785 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned approximately 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Trading Up 2.2%

NASDAQ SNOA opened at $1.38 on Thursday. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $4.82. The company has a market capitalization of $6.61 million, a price-to-earnings ratio of -1.13 and a beta of 1.28. The stock’s 50 day moving average is $1.23 and its two-hundred day moving average is $1.70.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Thursday, August 6th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative return on equity of 21.41% and a negative net margin of 10.33%.The business had revenue of $6.41 million during the quarter, compared to the consensus estimate of $4.99 million.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.